VLX 1570

Drug Profile

VLX 1570

Alternative Names: VLX1570

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vivolux
  • Developer Karolinska Institute; Mayo Clinic; Vivolux
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Deubiquitinating enzyme inhibitors; Proteasome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Waldenstrom's macroglobulinaemia

Most Recent Events

  • 01 Jun 2017 Vivolux suspends enrolment in a phase-I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA and Finland (IV) (NCT02372240)
  • 08 Apr 2015 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Finland (IV) (NCT02372240)
  • 07 Oct 2014 Preclinical trials in Multiple myeloma (treatment-resistant) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top